Hypersensitivity to doravirine or any of the excipients listed in section 6.1 of the relevant Summary of Product Characteristics1,2
DELSTRIGO2 | PIFELTRO1 | |
---|---|---|
Anticonvulsants
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin |
![]() |
![]() |
Antimycobacterials
Rifampicin, rifapentine |
![]() |
![]() |
Herbal products
St. John's wort |
![]() |
![]() |
Mitotane | ![]() |
![]() |
Enzalutamide | ![]() |
![]() |
Lumacaftor | ![]() |
![]() |
- Co-administration with medicinal products that are strong cytochrome P450 (CYP)3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of DELSTRIGO/PIFELTRO. These medicinal products include but are not limited to the above.